What are the contraindications and precautions of Ryeqo?

Ryeqo's contraindications include pregnancy, people who have been suffering from osteoporosis, etc. It is recommended that patients lose bone in the branch and increase blood pressure during treatment to avoid side effects that may harm their health.

Indications of Ryeqo

1. Heavy menstrual bleeding related to uterine leiomyomas:

It is suitable for the treatment of heavy menstrual bleeding related to uterine leiomyomas (fibromas) in premenopausal women.

2. Moderate to severe pain associated with endometriosis:

Ryeqo is indicated for the treatment of moderate to severe pain associated with endometriosis in premenopausal women.

3. Use restrictions:

Because Ryeqo may have a risk of irreversible and sustained bone loss, the use of this drug should be limited to 24 months.

Contraindications

Ryeqo is contraindicated in the following groups:

1. Thrombotic disorders:

Combinations of estrogens and progestins, including the estradiol/quinolone acetate component of Ryeqo, may increase the risk of thrombosis or thromboembolic disorders, including pulmonary embolism, stroke and myocardial infarction, and deep vein thrombosis, especially in women who are at high risk for these events. Overall, women older than 35 who smoke and those with dyslipidemia, uncontrolled hypertension, vascular disease or obesity are at greatest risk.

Two thromboembolic events occurred in a woman 38 days after receiving MYFEMBREE for moderate to severe pain associated with endometriosis.

2. Pregnancy:

Exposure to Ryeqo in early pregnancy may increase the risk of early pregnancy loss.

3. People with known osteoporosis:

Because Ryeqo carries the risk of further bone loss, patients with known osteoporosis should not take it to avoid worsening discomfort.

4. Malignant tumors:

Currently or in the past have breast cancer or other hormone-sensitive malignant tumors, and the risk of developing hormone-sensitive malignant tumors is increased.

5. Liver damage:

Suffering from known liver damage or disease.

6. Bleeding:

Undiagnosed abnormal uterine bleeding.

7. Anaphylaxis:

Known allergic reactions, angioedema or hypersensitivity to Ryeqo or any of its components, anaphylactoid reactions, urticaria and angioedema have been reported.

Medication Guide

1. Pre-medication examination:

Pregnancy should be ruled out and hormonal contraceptives should be stopped before pregnancy.

2. Recommendation:

Take one tablet orally once a day.

3. Missed dose:

Take the missed dose of Ryeqo as soon as possible that day, and then resume regular dosing at the normal time the next day.

4. P-gp inhibitors:

If concurrent use of oral P-gp inhibitors cannot be avoided, take Ryeqo at least 6 hours before taking the P-gp inhibitor.

5. Drug overdose:

Excessive estrogen plus progesterone may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness, fatigue and withdrawal bleeding. If overdose occurs, supportive care is recommended. The amount of relugolix, estradiol, or quinolone eliminated by hemodialysis is unknown.

Precautions

1.:

If arterial or venous thrombosis, cardiovascular or cerebrovascular events occur or are suspected, please stop using Ryeqo immediately. If feasible, discontinue Ryeqo at least 4-6 weeks before surgery in which the risk of thromboembolism is increased, or during prolonged immobilization.

2. Ocular symptoms:

If you suddenly develop unexplained partial or complete blindness, proptosis, diplopia, papilledema, or retinal vasculopathy, discontinue Ryeqo immediately and evaluate for retinal vein thrombosis, as it has been reported in patients receiving estrogen and progestin therapy.

3. Bone loss:

Ryeqo is contraindicated in women with known osteoporosis. Consider the benefits and risks of treatment with Ryeqo in patients with a history of low-trauma fractures or risk factors for osteoporosis or bone loss, including taking medications that may reduce bone mineral density (BMD) (e.g., systemic or long-term inhaled corticosteroids, anticonvulsants, or long-term use of proton pump inhibitors).

4. Suicidal ideation and mood disorders (including depression):

Before initiating treatment, assess patients with a history of suicidal ideation, depression, and mood disorders. Monitor patients for changes in mood and symptoms of depression, including soon after starting treatment, to determine whether the risks of continuing treatment with Ryeqo outweigh the benefits.

5. Liver damage and elevated transaminase levels:

It is recommended that patients pay attention to the signs and symptoms of liver damage.

6. Increased blood pressure:

Ryeqo will cause the patient's blood pressure to increase, so women with uncontrolled high blood pressure are contraindicated in its use. For women with well-controlled hypertension, continue to monitor blood pressure and discontinue use of Ryeqo if blood pressure increases significantly.

7. Changes in menstrual bleeding patterns and reduced ability to identify pregnancy:

Exclude pregnancy before starting to take Ryeqo[. Start taking Ryeqo as soon as possible after your period starts, but no later than 7 days after your period starts. If Ryeqo is started late in the menstrual cycle, irregular or heavy bleeding may occur initially. Women taking Ryeqo may experience amenorrhea, or a decrease in the amount, intensity, or duration of menstrual bleeding, which may delay the ability to recognize pregnancy. If pregnancy is suspected, take a pregnancy test and if pregnancy is confirmed, stop using Ryeqo.

8. Risk of early pregnancy loss:

Ryeqo can cause early pregnancy loss. It is recommended that women use effective non-hormonal contraceptive methods.

9. Uterine fibroid prolapse or expulsion:

Women with known or suspected submucosal uterine fibroids are advised to be aware of the possibility of uterine fibroid prolapse or prolapse, and are instructed to contact their doctor if they experience severe bleeding or cramping during treatment with Ryeqo.

10. Allergic reaction:

If an allergic reaction occurs, please stop using Ryeqo immediately.

11. History of gallbladder disease or cholestatic jaundice:

Use of Ryeqo should be discontinued. For women with a history of cholestatic jaundice associated with previous estrogen use or pregnancy if signs or symptoms of gallbladder disease or jaundice occur, assess the risk-benefit of continued treatment. Studies of estrogen users show a slightly increased relative risk of developing gallbladder disease.

Special medication groups

1. Pregnancy:

Because Ryeqo may cause spontaneous abortion, its use by pregnant people should be prohibited.

2. Lactation:

Due to animal experiments, Ryeqo was detected in the milk of lactating rats. Therefore, it was determined that the drug may also be present in human milk. Breastfeeding is not recommended for lactating people while taking this medication.

3. Women of childbearing potential:

Women of childbearing potential should use Ryeqo for contraception and use effective non-hormonal contraceptives during treatment and for at least 1 week after stopping the drug. However, concomitant use of hormonal contraceptives with Ryeqo should be avoided as it may increase the risk of estrogen-related adverse events and reduce therapeutic efficacy.

4. Medication in children:

Since the safety and effectiveness of Ryeqo in pediatric patients have not yet been determined, use by children is not recommended.

Recommended hot articles: